Replies to post #1374 on Marker Therapeutics Inc (MRKR)
11/20/11 6:01 PM
""Elegantly Simple’ Cancer and Infectious Disease Vaccine Uniquely Addresses Problems Found with Earlier Immunotherapy Approaches.....""
TapImmune President and CFO Denis Corin agrees: I think there are a lot of vaccine candidates that have gone through the mill and probably failed at Phase II or Phase III predominantly because the immune recognition and immune stimulation hasn’t been as effective as they needed it to be to come up with an end-level product. TAP is elegantly simple and we believe applicable across multiple types of cancers.
""When Tapimmune is recognized as an immunotherapy play along with the likes of Northwest BioTherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), the market cap of Tapimmune is expected by some analysts to hit a market cap of $100 million, or a stock price of $1.50......""
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |